CEL-SCI Corporation Announces 5-Year Head & Neck Cancer Survival Increased From 45% To 73% In Co's Target Population, Cutting Risk Of Death In Half, As Presented At Leading Cancer Conference ESMO 2023
Portfolio Pulse from Happy Mohamed
CEL-SCI Corporation (NYSE:CVM) has announced that its immunotherapy drug Multikine has increased 5-year survival rates from 45% to 73% in its target population of head and neck cancer patients. The company has finalized the selection criteria for this target population and plans to seek immediate approval for commercial distribution. Pre-application regulatory filings have been submitted in the UK and Europe, with additional filings planned in the U.S. and Canada.
October 23, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CEL-SCI's announcement of increased survival rates due to Multikine and plans for immediate approval for commercial distribution could potentially boost investor confidence and positively impact the company's stock price.
The announcement of increased survival rates due to Multikine is a significant development for CEL-SCI. This, coupled with the company's plans to seek immediate approval for commercial distribution, could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100